标题
Investigational therapies for hypercholesterolemia
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 5, Pages 603-617
出版商
Informa UK Limited
发表日期
2017-04-04
DOI
10.1080/13543784.2017.1315407
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors
- (2017) Yongzhi Chang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
- (2016) Peter H. Jones et al. AMERICAN JOURNAL OF CARDIOLOGY
- Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead—Pro: Table.
- (2016) Philip J. Barter et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer ProteinSignificance
- (2016) Gissette Reyes-Soffer et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia
- (2016) Hidenori Arai et al. ATHEROSCLEROSIS
- microRNAs in lipoprotein metabolism and cardiometabolic disorders
- (2016) Noemi Rotllan et al. ATHEROSCLEROSIS
- Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
- (2016) Michel Farnier et al. ATHEROSCLEROSIS
- PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement
- (2016) Nicola Ferri et al. ATHEROSCLEROSIS
- RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
- (2016) Dean Gilham et al. ATHEROSCLEROSIS
- PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
- (2016) Jin M. Cheng et al. ATHEROSCLEROSIS
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice
- (2016) Massimo F. Piepoli et al. ATHEROSCLEROSIS
- Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
- (2016) Ioanna Gouni-Berthold et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
- (2016) Florian Kronenberg CARDIOVASCULAR DRUGS AND THERAPY
- PCSK9 Association With Lipoprotein(a)Novelty and Significance
- (2016) Hagai Tavori et al. CIRCULATION RESEARCH
- MicroRNA Regulation of Atherosclerosis
- (2016) Mark W. Feinberg et al. CIRCULATION RESEARCH
- Update on the molecular biology of dyslipidemias
- (2016) I. Ramasamy CLINICA CHIMICA ACTA
- Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
- (2016) Andres Digenio et al. DIABETES CARE
- No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
- (2016) Helen M. Colhoun et al. EUROPEAN HEART JOURNAL
- Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
- (2016) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk
- (2016) Haralampos Milionis et al. European Journal of Internal Medicine
- Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis
- (2016) Wan Peng et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases
- (2016) Masahiro Ikenaga et al. Journal of Atherosclerosis and Thrombosis
- Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial
- (2016) Harold E. Bays et al. Journal of Clinical Lipidology
- LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design
- (2016) Dirk J. Blom et al. Journal of Clinical Lipidology
- Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses
- (2016) Julian C. van Capelleveen et al. Journal of Clinical Lipidology
- Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia
- (2016) Frederick J. Raal et al. Journal of Clinical Lipidology
- Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients
- (2016) Evan Stein et al. Journal of Clinical Lipidology
- Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
- (2016) P. Barton Duell et al. Journal of Clinical Lipidology
- Effect of evolocumab on cholesterol synthesis and absorption
- (2016) Matthew Peach et al. JOURNAL OF LIPID RESEARCH
- Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
- (2016) Børge G. Nordestgaard et al. JOURNAL OF LIPID RESEARCH
- Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
- (2016) Xiaohong Yang et al. JOURNAL OF LIPID RESEARCH
- Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
- (2016) Sabina A. Murphy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
- (2016) Nicholas J Viney et al. LANCET
- Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo
- (2016) Peter P. Toth et al. Lipids in Health and Disease
- Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
- (2016) Charles J. Glueck et al. Lipids in Health and Disease
- Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center
- (2016) Parth Shah et al. Lipids in Health and Disease
- Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial
- (2016) Andrew L. Siebel et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence
- (2016) Nicola Ferri et al. Translational Research
- The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking
- (2016) Ren Zhang Open Biology
- Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
- (2016) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol
- (2015) Jamal S. Rana et al. AMERICAN JOURNAL OF CARDIOLOGY
- Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
- (2015) Christie M. Ballantyne et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial
- (2015) Stephen J. Nicholls et al. American Journal of Cardiovascular Drugs
- Intestinal scavenger receptor class B type I as a novel regulator of chylomicron production in healthy and diet-induced obese states
- (2015) Marsel Lino et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaSignificance
- (2015) Raul D. Santos et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis
- (2015) M. Lucrecia Alvarez et al. ATHEROSCLEROSIS
- On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects
- (2015) Hagai Tavori et al. ATHEROSCLEROSIS
- microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator
- (2015) Huajun Jiang et al. ATHEROSCLEROSIS
- Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-ITCLINICAL PERSPECTIVES
- (2015) Erin A. Bohula et al. CIRCULATION
- Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia
- (2015) Amirhossein Sahebkar et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials
- (2015) R. R. Henry et al. DIABETES OBESITY & METABOLISM
- The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
- (2015) Michael J. Lipinski et al. EUROPEAN HEART JOURNAL
- Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
- (2015) Michael M. Page et al. EXPERT OPINION ON PHARMACOTHERAPY
- Newly developed apolipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo
- (2015) Tomohiko Shimizu et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Association of Cardiometabolic Multimorbidity With Mortality
- (2015) Emanuele Di Angelantonio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
- (2015) John S. Millar et al. JOURNAL OF CLINICAL INVESTIGATION
- Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia
- (2015) Raul D. Santos et al. Journal of Clinical Lipidology
- The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis
- (2015) Moritz C. Wyler von Ballmoos et al. Journal of Clinical Lipidology
- Efficacy and safety of mipomersen in treatment of dyslipidemia: A meta-analysis of randomized controlled trials
- (2015) Raju Panta et al. Journal of Clinical Lipidology
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population
- (2015) Lin Ding et al. JOURNAL OF LIPID RESEARCH
- ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys
- (2015) Viktoria Gusarova et al. JOURNAL OF LIPID RESEARCH
- Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA
- (2015) Ruud S. Kootte et al. JOURNAL OF LIPID RESEARCH
- Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib
- (2015) Stephen J. Nicholls et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
- (2015) G Kees Hovingh et al. LANCET
- Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
- (2015) John J P Kastelein et al. LANCET
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome
- (2015) Charles Daniel Meyers et al. Lipids in Health and Disease
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid Target Achievement Among Patients With Very High and High Cardiovascular Risk in a Lipid Clinic
- (2014) Fotios Barkas et al. ANGIOLOGY
- Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus
- (2014) Maria J. Gutierrez et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Association of cholesteryl ester transfer protein (CETP) gene polymorphism, high density lipoprotein cholesterol and risk of coronary artery disease: a meta-analysis using a Mendelian randomization approach
- (2014) Zhijun Wu et al. BMC Medical Genetics
- Lipoprotein(a)
- (2014) Florian Kronenberg CIRCULATION
- In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I
- (2014) Yannan Zhao et al. JOURNAL OF LIPID RESEARCH
- Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults
- (2014) Jeffrey G. Suico et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
- (2014) Anand Rohatgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance
- (2014) S. Rabar et al. BMJ-British Medical Journal
- Therapeutic Silencing of MicroRNA-33 Inhibits the Progression of Atherosclerosis in Ldlr −/− Mice—Brief Report
- (2013) Noemi Rotllan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease
- (2013) Josef Leebmann et al. CIRCULATION
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. CIRCULATION
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression
- (2013) Rex A. Parker et al. JOURNAL OF LIPID RESEARCH
- ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK
- (2013) Sergey Filippov et al. JOURNAL OF LIPID RESEARCH
- MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion
- (2013) James Soh et al. NATURE MEDICINE
- Genetic Associations with Valvular Calcification and Aortic Stenosis
- (2013) George Thanassoulis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol
- (2012) Vineeta Sharma et al. CURRENT OPINION IN LIPIDOLOGY
- AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism
- (2012) Stephen L. Pinkosky et al. JOURNAL OF LIPID RESEARCH
- Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
- (2012) Marina Cuchel et al. LANCET
- Apolipoprotein A-V dependent modulation of plasma triacylglycerol: A puzzlement
- (2011) Vineeta Sharma et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease
- (2011) Carlos O. Mendivil et al. CIRCULATION
- Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis
- (2011) Katey J. Rayner et al. JOURNAL OF CLINICAL INVESTIGATION
- Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure
- (2011) Guoqing Cao et al. JOURNAL OF LIPID RESEARCH
- Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype
- (2010) Chunyu Zheng et al. CIRCULATION
- Lipoprotein(a) and Risk of Type 2 Diabetes
- (2010) S. Mora et al. CLINICAL CHEMISTRY
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Pharmacological Characterization of Diethyl-2-( acetyloxymethyl)-2-phenylmalonate (JTT-130), an Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein
- (2010) Y. Mera et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- miR-33 links SREBP-2 induction to repression of sterol transporters
- (2010) T. J. Marquart et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MiR-33 Contributes to the Regulation of Cholesterol Homeostasis
- (2010) K. J. Rayner et al. SCIENCE
- Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)
- (2009) Helen M. Colhoun et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
- (2009) Pia R. Kamstrup JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
- (2009) Robert Clarke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acylation of Acylglycerols by Acyl Coenzyme A:Diacylglycerol Acyltransferase 1 (DGAT1)
- (2008) Dong Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now